Mesenchymal Stem Cells in the Treatment of Subjects with Advance Chronic Obstructive Pulmonary Disease (COPD)

Phase 1

Active, not recruiting

• Conditions: Chronic Obstructive Pulmonary Disease
• Interventions: Biological: Mesenchymal Stem Cells

• Registration Number: NCT04047810
• Lead Sponsor: Mayo Clinic

Brief Summary

Researchers are trying to understand the effects of mesenchymal stem cells therapy in subjects with advance chronic obstructive pulmonary disease

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-08-05
• Study First Submitted QC: 2019-08-05
• Study First Posted: 2019-08-07
• Study Start: 2020-01-06
• Primary Completion: 2023-11-21
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-27
• Last Update Posted: 2025-03-03
• Study Completion: 2025-08

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Subjects with Advanced Chronic Obstructive Pulmonary Disease	Mesenchymal Stem Cells	Subjects diagnosed with severe or very severe COPD will be infused intravenously with Mesenchymal Stem Cells (MSC)

Primary Outcome Measures

Name	Time	Method
Adverse Events	One hour post completion of infusion	Number of subjects to tolerate IV infusion of Mesenchymal Stem Cells (MSC) without acute clinical or physiological deterioration

Trial Locations

Locations (1)

Mayo Clinic in Florida; 🇺🇸 Jacksonville, Florida, United States